Prof. Dr. Gerd Bendas

Pharmazeutisches Institut
Pharmazeutische und zellbiologische Chemie
An der Immenburg 4
53121 Bonn
Fon: +49-228-73-5250
Fax: +49-228-73-4692
Mail: [Email protection active, please enable JavaScript.]

« Oktober 2022 »
Mo Di Mi Do Fr Sa So
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
Sie sind hier: Startseite Publikationen




Bendas G
Pentosan Polysulfate-A "Better Heparin" as Potential Medication for the Treatment of SARS-CoV-2 Infections?
Thromb Haemost 2022; 122(6):870. doi: 10.1055/a-1815-2142.

Bendas G, Schlesinger M.
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer development and metastasis.
Exp Hematol Oncol 2022; 11(1):19. doi: 10.1186/s40164-022-00273-2.

Gockel LM, Nekipelov K, Ferro V, Bendas G, Schlesinger M.
Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin.
Cancer Immunol Immunother 2022. doi: 10.1007/s00262-022-03186-5.

Gockel LM, Pfeifer V, Baltes F, Bachmaier RD, Wagner KG, Bendas G, Gütschow M, Sosič I, Steinebach C.
Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models.
Arch Pharm (Weinheim) 2022:e202100467. doi: 10.1002/ardp.202100467.

Keuler T, König B, Bückreiß N, Kraft FB, König P, Schäker-Hübner L, Steinebach C, Bendas G, Gütschow M, Hansen F. K
Development of the first non-hydroxamate selective HDAC6 degraders.
Chem Commun (Camb) 2022. doi: 10.1039/d2cc03712b
geteilte Erstautorenschaft Keuler & König & Bückreiß.

Schäker-Hübner L, Haschemi R, Büch T, Kraft FB, Brumme B, Schöler A, Jenke R, Meiler J, Aigner A, Bendas G, Hansen F. K
Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors.
ChemMedChem 2022:e202100755. doi: 10.1002/cmdc.202100755.

Wang Y, Liu X, Obser T, Bauer AT, Heyes M, Starzonek S, Zulal M, Opitz K, Ott L, Riethdorf S, Lange T, Pantel K, Bendas G, Schneider SW, Kusche-Gullberg M, Gorzelanny C.
Heparan sulfate dependent binding of plasmatic von Willebrand factor to blood circulating melanoma cells attenuates metastasis.
Matrix Biol 2022. doi: 10.1016/j.matbio.2022.06.002.


Gockel LM, Heyes M, Li H, Al Nahain A, Gorzelanny C, Schlesinger M, Holdenrieder S, Li J-P, Ferro V, Bendas G.
Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics.
ACS Appl Mater Interfaces 2021; 13(6):7080–93. doi: 10.1021/acsami.0c20744.

Haschemi R, Gockel LM, Bendas G, Schlesinger M.
A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells.
Int J Mol Sci 2021; 22(7). doi: 10.3390/ijms22073323.

Haschemi R, Kobelt D, Steinwarz E, Schlesinger M, Stein U, Bendas G.
Insulin-like Growth Factor Binding Protein-2 (IGFBP2) Is a Key Molecule in the MACC1-Mediated Platelet Communication and Metastasis of Colorectal Cancer Cells.
Int J Mol Sci 2021; 22(22). doi: 10.3390/ijms222212195.

Hörömpöli D, Ciglia C, Glüsenkamp K-H, Haustedt LO, Falkenstein-Paul H, Bendas G, Berscheid A, Brötz-Oesterhelt H.
The Antibiotic Negamycin Crosses the Bacterial Cytoplasmic Membrane by Multiple Routes.
Antimicrob Agents Chemother 2021; 65(4). doi: 10.1128/AAC.00986-20.

Lopez V, Schäkel L, Schuh HJM, Schmidt MS, Mirza S, Renn C, Pelletier J, Lee S-Y, Sévigny J, Alban S, Bendas G, Müller C. E
Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39.
Mar Drugs 2021; 19(2). doi: 10.3390/md19020051.

Schwarz S, Schlesinger M, Bendas G.
Detection of Tumor Cell-Induced Platelet Aggregation and Granule Secretion.
Methods Mol Biol 2021; 2294:181–95. doi: 10.1007/978-1-0716-1350-4_13.

 Sosič I, Gobec M, Steinebach C, Schlesinger M, Bendas G, Gütschow M.
Another structural correction for 1-oxo-1H-phenalene-2,3-dicarbonitriles: Synthesis of a potent BCL-2 inhibiting 7-phenoxy derivative.
Arch Pharm (Weinheim) 2021; 354(10):e2100151. doi: 10.1002/ardp.202100151.


Baltes F, Caspers J, Henze S, Schlesinger M, Bendas G.
Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β1-integrin Emerges as a Key Factor for Breast Cancer Chemosensitization upon Collagen Type 1 Binding.
Int J Mol Sci 2020; 21(14). doi: 10.3390/ijms21144956.

Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G.
β1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters.
Biochim Biophys Acta Mol Cell Res 2020; 1867(5):118663. doi: 10.1016/j.bbamcr.2020.118663.

Bendas G, Borsig L.
Heparanase in Cancer Metastasis - Heparin as a Potential Inhibitor of Cell Adhesion Molecules.
Adv Exp Med Biol 2020; 1221:309–29. doi: 10.1007/978-3-030-34521-1_11.

Korff M, Imberg L, Will JM, Bückreiß N, Kalinina SA, Wenzel BM, Kastner GA, Daniliuc CG, Barth M, Ovsepyan RA, Butov KR, Humpf H-U, Lehr M, Panteleev MA, Poso A, Karst U, Steinmetzer T, Bendas G, Kalinin D. V
Acylated 1H-1,2,4-Triazol-5-amines Targeting Human Coagulation Factor XIIa and Thrombin: Conventional and Microscale Synthesis, Anticoagulant Properties, and Mechanism of Action.
J Med Chem 2020; 63(21):13159–86. doi: 10.1021/acs.jmedchem.0c01635.

Schwarz S, Gockel LM, Naggi A, Barash U, Gobec M, Bendas G, Schlesinger M.
Glycosaminoglycans as Tools to Decipher the Platelet Tumor Cell Interaction: A Focus on P-Selectin.
Molecules 2020; 25(5). doi: 10.3390/molecules25051039.

Silbermann K, Li J, Namasivayam V, Baltes F, Bendas G, Stefan SM, Wiese M.
Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists.
J Med Chem 2020; 63(18):10412–32. doi: 10.1021/acs.jmedchem.0c00961.

Steinebach C, Ng YLD, Sosič I, Lee C-S, Chen S, Lindner S, Vu LP, Bricelj A, Haschemi R, Monschke M, Steinwarz E, Wagner KG, Bendas G, Luo J, Gütschow M, Krönke J.
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders.
Chem Sci 2020; 11(13):3474–86. doi: 10.1039/d0sc00167h.

Wantoch von Rekowski K, König P, Henze S, Schlesinger M, Zawierucha P, Januchowski R, Bendas G.
Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies.
Int J Mol Sci 2020; 21(23). doi: 10.3390/ijms21239240
geteilte Erstautorenschaft Wantoch & König.


Bargen K von, Scraba M, Krämer I, Ketterer M, Nehls C, Krokowski S, Repnik U, Wittlich M, Maaser A, Zapka P, Bunge M, Schlesinger M, Huth G, Klees A, Hansen P, Jeschke A, Bendas G, Utermöhlen O, Griffiths G, Gutsmann T, Wohlmann J, Haas A.
Virulence-associated protein A from Rhodococcus equi is an intercompartmental pH-neutralising virulence factor.
Cell Microbiol 2019; 21(1):e12958. doi: 10.1111/cmi.12958.

Wantoch von Rekowski K, König P, Henze S, Schlesinger M, Zawierucha P, Januchowski R, Bendas G.
The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.
Biomolecules 2019; 9(12). doi: 10.3390/biom9120788.


Gockel LM, Ponert JM, Schwarz S, Schlesinger M, Bendas G.
The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
Molecules 2018; 23(11). doi: 10.3390/molecules23112753
geteilte Erstautorenschaft Gockel & Ponert.

Hoß SG, Grundmann M, Benkel T, Gockel LM, Schwarz S, Kostenis E, Schlesinger M, Ilan N, Vlodavsky I, Bendas G.
Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Thromb Haemost 2018; 118(10):1803–14. doi: 10.1055/s-0038-1669922.

Jakubzig B, Baltes F, Henze S, Schlesinger M, Bendas G.
Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells-Deciphering Novel Potential Targets for a Cell Sensitization.
Cancers (Basel) 2018; 10(12). doi: 10.3390/cancers10120495
geteilte Erstautorenschaft Jakubzig & Baltes.

Ponert JM, Gockel LM, Henze S, Schlesinger M.
Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells.
Molecules 2018; 23(10). doi: 10.3390/molecules23102690.

Ponert JM, Schwarz S, Haschemi R, Müller J, Pötzsch B, Bendas G, Schlesinger M.
The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.
PLoS One 2018; 13(1):e0191303. doi: 10.1371/journal.pone.0191303.

Schlesinger M
Role of platelets and platelet receptors in cancer metastasis.
J Hematol Oncol 2018; 11(1):125. doi: 10.1186/s13045-018-0669-2.


Hoß SG, Bendas G.
Mass-Sensitive Biosensor Systems to Determine the Membrane Interaction of Analytes.
Methods Mol Biol 2017; 1520:145–57. doi: 10.1007/978-1-4939-6634-9_9.

Hoß SG, Schlesinger M, Bendas G.
The matricellular ligand Cyr61 contributes to the metastatic spread of tumors by activating integrin VLA-4, independently of thiol redox modulation.
Int J Clin Pharmacol Ther 2017; 55(8):682–5. doi: 10.5414/CPXCES15EA03.

Mueller T, Pfankuchen DB, Wantoch von Rekowski K, Schlesinger M, Reipsch F, Bendas G.
The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Molecules 2017; 22(5). doi: 10.3390/molecules22050728.

Pfankuchen DB, Baltes F, Batool T, Li J-P, Schlesinger M, Bendas G.
Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.
Oncotarget 2017; 8(40):67553–66. doi: 10.18632/oncotarget.18738.

Piva MBR, Jakubzig B, Bendas G.
Integrin Activation Contributes to Lower Cisplatin Sensitivity in MV3 Melanoma Cells by Inducing the Wnt Signalling Pathway.
Cancers (Basel) 2017; 9(9). doi: 10.3390/cancers9090125
geteilte Erstautorenschaft Piva & Jakubzig.


Bisht S, Schlesinger M, Rupp A, Schubert R, Nolting J, Wenzel J, Holdenrieder S, Brossart P, Bendas G, Feldmann G.
A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
J Nanobiotechnology 2016; 14(1):57. doi: 10.1186/s12951-016-0209-6.

Ross T, Jakubzig B, Grundmann M, Massing U, Kostenis E, Schlesinger M, Bendas G.
The molecular mechanism by which saturated lysophosphatidylcholine attenuates the metastatic capacity of melanoma cells.
FEBS Open Bio 2016; 6(12):1297–309. doi: 10.1002/2211-5463.12152
geteilte Erstautorenschaft Ross & Jakubzig.


Calin M, Stan D, Schlesinger M, Simion V, Deleanu M, Constantinescu CA, Gan A-M, Pirvulescu MM, Butoi E, Manduteanu I, Bota M, Enachescu M, Borsig L, Bendas G, Simionescu M.
VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes.
Eur J Pharm Biopharm 2015; 89:18–29. doi: 10.1016/j.ejpb.2014.11.016.

Gerber U, Hoß SG, Shteingauz A, Jüngel E, Jakubzig B, Ilan N, Blaheta R, Schlesinger M, Vlodavsky I, Bendas G.
Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Semin Thromb Hemost 2015; 41(2):244–54. doi: 10.1055/s-0035-1544229.

Münch D, Engels I, Müller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G, Grein F, Bendas G, Sahl H-G, Schneider T.
Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
Antimicrob Agents Chemother 2015; 59(2):772–81. doi: 10.1128/AAC.02663-14.

Pfankuchen DB, Stölting DP, Schlesinger M, Royer H-D, Bendas G.
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
Biochem Pharmacol 2015; 97(2):147–57. doi: 10.1016/j.bcp.2015.07.013.

Raynor A, Jantscheff P, Ross T, Schlesinger M, Wilde M, Haasis S, Dreckmann T, Bendas G, Massing U.
Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases.
Lipids Health Dis 2015; 14:69. doi: 10.1186/s12944-015-0070-x.

Roblek M, Calin M, Schlesinger M, Stan D, Zeisig R, Simionescu M, Bendas G, Borsig L.
Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis.
J Control Release 2015; 220(Pt A):341–7. doi: 10.1016/j.jconrel.2015.10.055.

Ross T, Heuter S, Schlesinger M, Jakubzig B, Raynor A, Massing U, Bendas G.
Lysophosphatidylcholine attenuates melanoma cell adhesion and migration dependent on the degree of fatty acid saturation.
Int J Clin Pharmacol Ther 2015; 53(12):1049–51. doi: 10.5414/CPXCES14EA05.

Schlesinger M, Bendas G.
Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis.
Cancer Metastasis Rev 2015; 34(4):575–91. doi: 10.1007/s10555-014-9545-x.

Schlesinger M, Bendas G.
Vascular cell adhesion molecule-1 (VCAM-1)--an increasing insight into its role in tumorigenicity and metastasis.
Int J Cancer 2015; 136(11):2504–14. doi: 10.1002/ijc.28927.

Schlesinger M, Zeisig R, Ortmann K, Calin M, Gerber U, Roblek M, Borsig L, Bendas G.
Inhibition of chemokine receptor CCR2 reduces sarcoma cell transendothelial migration and metastasis to the lungs.
Int J Clin Pharmacol Ther 2015; 53(12):1046–8. doi: 10.5414/CPXCES14EA04.


Schlesinger M, Roblek M, Ortmann K, Naggi A, Torri G, Borsig L, Bendas G.
The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Thromb Res 2014; 133(5):855–62. doi: 10.1016/j.thromres.2014.02.020.

Schütte U, Bisht S, Heukamp LC, Kebschull M, Florin A, Haarmann J, Hoffmann P, Bendas G, Buettner R, Brossart P, Feldmann G.
Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.
Transl Oncol 2014; 7(2):309–21. doi: 10.1016/j.tranon.2014.02.005.

Stölting DP, Koch M, Wiese M, Royer H-D, Bendas G.
Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathway.
Int J Clin Pharmacol Ther 2014; 52(1):78–81. doi: 10.5414/CPXCES13EA03.

Stölting DP, Borrmann M, Koch M, Wiese M, Royer H-D, Bendas G.
How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cells.
Anticancer Res 2014; 34(1):525–30.


Koch M, Krieger ML, Stölting D, Brenner N, Beier M, Jaehde U, Wiese M, Royer H-D, Bendas G.
Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling.
Biochem Pharmacol 2013; 85(8):1077–90. doi: 10.1016/j.bcp.2013.01.028.

Meschenmoser K, Kim Y, Franken S, Nowak M, Feldmann G, Bendas G, Wolfgarten M, Messmer D, Schmidt-Wolf I. GH
Targeting cancer with a bi-functional peptide: in vitro and in vivo results.
In Vivo 2013; 27(4):431–42.

Reder-Christ K, Schmitz P, Bota M, Gerber U, Falkenstein-Paul H, Fuss C, Enachescu M, Bendas G.
A dry membrane protection technique to allow surface acoustic wave biosensor measurements of biological model membrane approaches.
Sensors (Basel) 2013; 13(9):12392–405. doi: 10.3390/s130912392.

Schmitz P, Gerber U, Schütze N, Jüngel E, Blaheta R, Naggi A, Torri G, Bendas G.
Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Thromb Haemost 2013; 110(5):1046–54. doi: 10.1160/TH13-02-0158.

Schmitz P, Gerber U, Jüngel E, Schütze N, Blaheta R, Bendas G.
Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro.
Int J Clin Pharmacol Ther 2013; 51(1):47–50. doi: 10.5414/cpp51047.

Schneider V, Krieger ML, Bendas G, Jaehde U, Kalayda G. V
Contribution of intracellular ATP to cisplatin resistance of tumor cells.
J Biol Inorg Chem 2013; 18(2):165–74. doi: 10.1007/s00775-012-0960-6.

Stölting DP, Jaehde U, Wiese M, Bendas G.
Are low molecular weight heparins able to sensitize chemoresistant tumor cells?
Int J Clin Pharmacol Ther 2013; 51(1):70–3. doi: 10.5414/cpp51070.


Müller A, Münch D, Schmidt Y, Reder-Christ K, Schiffer G, Bendas G, Gross H, Sahl H-G, Schneider T, Brötz-Oesterhelt H.
Lipodepsipeptide empedopeptin inhibits cell wall biosynthesis through Ca2+-dependent complex formation with peptidoglycan precursors.
J Biol Chem 2012; 287(24):20270–80. doi: 10.1074/jbc.M112.369561.

Reder-Christ K, Schmidt Y, Dörr M, Sahl H-G, Josten M, Raaijmakers JM, Gross H, Bendas G.
Model membrane studies for characterization of different antibiotic activities of lipopeptides from Pseudomonas.
Biochim Biophys Acta 2012; 1818(3):566–73. doi: 10.1016/j.bbamem.2011.08.007.

Schlesinger M, Schmitz P, Zeisig R, Naggi A, Torri G, Casu B, Bendas G.
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Thromb Res 2012; 129(5):603–10. doi: 10.1016/j.thromres.2011.10.023.


Jantscheff P, Schlesinger M, Fritzsche J, Taylor LA, Graeser R, Kirfel G, Fürst DO, Massing U, Bendas G.
Lysophosphatidylcholine pretreatment reduces VLA-4 and P-Selectin-mediated b16.f10 melanoma cell adhesion in vitro and inhibits metastasis-like lung invasion in vivo.
Mol Cancer Ther 2011; 10(1):186–97. doi: 10.1158/1535-7163.MCT-10-0474.

Reder-Christ K, Falkenstein-Paul H, Klocek G, Al-Kaddah S, Bakowsky U, Bendas G.
Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin.
Int J Antimicrob Agents 2011; 37(3):256–60. doi: 10.1016/j.ijantimicag.2010.11.024.


Alexander M, Schlesinger M, Jantscheff P, Massing U, Bendas G.
Reduction in human melanoma cell adhesion receptor activity by lysophosphatidylcholine (LPC) treatment - functional characterization and signal pathway analyses.
Int J Clin Pharmacol Ther 2010; 48(7):478–80. doi: 10.5414/cpp48478.

Al-Kaddah S, Reder-Christ K, Klocek G, Wiedemann I, Brunschweiger M, Bendas G.
Analysis of membrane interactions of antibiotic peptides using ITC and biosensor measurements.
Biophys Chem 2010; 152(1-3):145–52. doi: 10.1016/j.bpc.2010.09.002.

Bendas G
Biosensor-based evaluation of liposomal binding behavior.
Methods Mol Biol 2010; 606:519–29. doi: 10.1007/978-1-60761-447-0_35.

Krieger ML, Konold A, Wiese M, Jaehde U, Bendas G.
Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells.
Int J Clin Pharmacol Ther 2010; 48(7):442–4. doi: 10.5414/cpp48442.

Krieger ML, Eckstein N, Schneider V, Koch M, Royer H-D, Jaehde U, Bendas G.
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
Int J Pharm 2010; 389(1-2):10–7. doi: 10.1016/j.ijpharm.2009.12.061.

Linnemann A, van der Ven PFM, Vakeel P, Albinus B, Simonis D, Bendas G, Schenk JA, Micheel B, Kley RA, Fürst D. O
The sarcomeric Z-disc component myopodin is a multiadapter protein that interacts with filamin and alpha-actinin.
Eur J Cell Biol 2010; 89(9):681–92. doi: 10.1016/j.ejcb.2010.04.004.

Schlesinger M, Naggi A, Torri G, Zeisig R, Alexander M, Schmitz P, Casu B, Bendas G.
Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.
Int J Clin Pharmacol Ther 2010; 48(7):448–50. doi: 10.5414/cpp48448.

Schneider V, Kalayda GV, Krieger ML, Bendas G, Jaehde U.
Intracellular ATP depletion leads to reduced platinum accumulation in ovarian cancer cells.
Int J Clin Pharmacol Ther 2010; 48(7):456–8. doi: 10.5414/cpp48456.

Simonis D, Schlesinger M, Seelandt C, Borsig L, Bendas G.
Analysis of SM4 sulfatide as a P-selectin ligand using model membranes.
Biophys Chem 2010; 150(1-3):98–104. doi: 10.1016/j.bpc.2010.01.007.


Alban S, Ludwig RJ, Bendas G, Schön MP, Oostingh GJ, Radeke HH, Fritzsche J, Pfeilschifter J, Kaufmann R, Boehncke W.-H.
PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions.
J Invest Dermatol 2009; 129(5):1192–202. doi: 10.1038/jid.2008.358.

Schlesinger M, Simonis D, Schmitz P, Fritzsche J, Bendas G.
Binding between heparin and the integrin VLA-4.
Thromb Haemost 2009; 102(5):816–22. doi: 10.1160/TH09-01-0061.


Bakowsky H, Richter T, Kneuer C, Hoekstra D, Rothe U, Bendas G, Ehrhardt C, Bakowsky U.
Adhesion characteristics and stability assessment of lectin-modified liposomes for site-specific drug delivery.
Biochim Biophys Acta 2008; 1778(1):242–9. doi: 10.1016/j.bbamem.2007.09.033.

Christ K, Al-Kaddah S, Wiedemann I, Rattay B, Sahl H-G, Bendas G.
Membrane lipids determine the antibiotic activity of the lantibiotic gallidermin.
J Membr Biol 2008; 226(1-3):9–16. doi: 10.1007/s00232-008-9134-4.

Fritzsche J, Simonis D, Bendas G.
Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
Thromb Haemost 2008; 100(6):1166–75.

Gege C, Schumacher G, Rothe U, Schmidt RR, Bendas G.
Visualization of sialyl Lewis(X) glycosphingolipid microdomains in model membranes as selectin recognition motifs using a fluorescence label.
Carbohydr Res 2008; 343(14):2361–8. doi: 10.1016/j.carres.2008.07.004.

Gosk S, Moos T, Gottstein C, Bendas G.
VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo.
Biochim Biophys Acta 2008; 1778(4):854–63. doi: 10.1016/j.bbamem.2007.12.021.

Höpfner M, Rothe U, Bendas G.
Biosensor-based evaluation of liposomal behavior in the target binding process.
J Liposome Res 2008; 18(1):71–82. doi: 10.1080/08982100801894000.


Christ K, Wiedemann I, Bakowsky U, Sahl H-G, Bendas G.
The role of lipid II in membrane binding of and pore formation by nisin analyzed by two combined biosensor techniques.
Biochim Biophys Acta 2007; 1768(3):694–704. doi: 10.1016/j.bbamem.2006.12.003.

Simonis D, Christ K, Alban S, Bendas G.
Affinity and kinetics of different heparins binding to P- and L-selectin.
Semin Thromb Hemost 2007; 33(5):534–9. doi: 10.1055/s-2007-982085.

Simonis D, Fritzsche J, Alban S, Bendas G.
Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition.
Biochemistry 2007; 46(20):6156–64. doi: 10.1021/bi602347g.


Fritzsche J, Alban S, Ludwig RJ, Rubant S, Boehncke W-H, Schumacher G, Bendas G.
The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity.
Biochem Pharmacol 2006; 72(4):474–85. doi: 10.1016/j.bcp.2006.05.006.

Schumacher G, Bakowsky U, Gege C, Schmidt RR, Rothe U, Bendas G.
Lessons learned from clustering of fluorinated glycolipids on selectin ligand function in cell rolling.
Biochemistry 2006; 45(9):2894–903. doi: 10.1021/bi052201r.

Schumacher G, Bendas G, Stahl B, Beermann C.
Human milk oligosaccharides affect P-selectin binding capacities: in vitro investigation.
Nutrition 2006; 22(6):620–7. doi: 10.1016/j.nut.2005.12.009.


Bendas G
Inhibitors of membrane receptors involved with leukocyte extravasation.
Mini Rev Med Chem 2005; 5(6):575–84. doi: 10.2174/1389557054023279.

Christ K, Rüttinger H-H, Höpfner M, Rothe U, Bendas G.
The detection of UV-induced membrane damages by a combination of two biosensor techniques.
Photochem Photobiol 2005; 81(6):1417–23. doi: 10.1562/2005-04-19-RA-493.

Fritzsche J, Hünerbein I, Schumacher G, Alban S, Ludwig R, Gille J, Bendas G.
In vitro investigation on the selectin binding mechanisms in tumor cell metastasis and their inhibition by heparin.
Int J Clin Pharmacol Ther 2005; 43(12):570–2. doi: 10.5414/cpp43570.

Gosk S, Gottstein C, Bendas G.
Targeting of immunoliposomes to endothelial cells expressing VCAM: a future strategy in cancer therapy.
Int J Clin Pharmacol Ther 2005; 43(12):581–2. doi: 10.5414/cpp43581.


Gege C, Schneider MF, Schumacher G, Limozin L, Rothe U, Bendas G, Tanaka M, Schmidt R. R
Functional microdomains of glycolipids with partially fluorinated membrane anchors: impact on cell adhesion.
Chemphyschem 2004; 5(2):216–24. doi: 10.1002/cphc.200300947.


Bendas G, Rothe U, Scherphof GL, Kamps J. AAM
The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes.
Biochim Biophys Acta 2003; 1609(1):63–70. doi: 10.1016/s0005-2736(02)00655-7.

Höpfner M, Alban S, Schumacher G, Rothe U, Bendas G.
Selectin-blocking semisynthetic sulfated polysaccharides as promising anti-inflammatory agents.
J Pharm Pharmacol 2003; 55(5):697–706. doi: 10.1211/002235703765344621.



ausgewählte Publikationen vor 2003

Schumacher, G., Höpfner, M., Vogel, J., Bakowsky, U., Ikami, T., Rothe, U., Bendas, G.
Ein dynamisches Testsystem zur Untersuchung Selektin-inhibierender Substanzen als potentiell antiinflammatorische Verbindungen.
Pharmind 64 (2002), 808-815.

Bakowsky, U., Schumacher, G., Gege, C., Schmidt, R.R., Rothe, U., Bendas, G.
Cooperation between lateral ligand mobility and accessibility for receptor recognition in selectin-induced cell rolling.
Biochemistry 41 (2002), 4704-4712.

Bendas, G.
Untersuchung des Selektin-vermittelten Leukozytenrollens: Ein neuartiger Ansatz zur antiinflammatorischen Therapie.
BIOspektrum 7 (2001), 41-42

Bakowsky, U., Bendas, G., Rothe, U., Kneuer, C., Bakowsky, H., Hoeckstra, D.
Quartz crystal microbalance and AFM: Powerful tools for the characterization of specific interactions of lectin/PEG-modified liposomes with glycolipid bilayers.
J. Control. Rel. (2001), 5164-5165.

Bendas, G.
Immunoliposomes- A new approach to targeting cancer therapy.
BioDrugs 15 (2001), 215-224.

Kessner, S., Krause, A., Rothe, U., Bendas, G.
Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells.
Biochim. Biophys. Acta 1514 (2001), 177-190.

Gege, C., Vogel, J., Bendas, G., Rothe, U., Schmidt, R.R.
Synthesis of the Sialyl Lewis X epitope attached to glycolipids with different core structures and their selectin-binding characteristics in a dynamic test system.
Chem. Eur. J. 6 (2000), 111-122.

Bendas, G., Krause, A., Bakowsky, U., Vogel, J., Rothe, U.
Targetability of novel immunoliposomes prepared by a new antibody conjugation technique.
Int. J. Pharm. 181 (1999), 79-93.

Vogel, J., Bendas, G., Bakowsky, U., Hummel, G., Schmidt, R.R., Kettmann, U., Rothe, U.
The role of glycolipids in mediating cell adhesion: A flow chamber study.
Biochim. Biophys. Acta 1372 (1998), 205-515.

Geyer, A., Reinhardt, S., Bendas, G., Rothe, U., Schmidt, R.R.
C2-symmetric Lewis antigen mimetics exhibiting the common structural motif.
J. Am. Chem. Soc. 119 (1997), 11707-11708.

Bendas, G., Vogel, J., Bakowsky, U., Krause, A., Müller, J., Rothe, U.
A Liposome-based model system for the stimulation of lectin-induced cell adhesion.
Biochim. Biophys. Acta 1325 (1997), 297-308.


Bendas G., Düfer M.
Update Biologicals: Rekombinante Proteine und ihr therapeutischer Einsatz.
1. Auflage 2016. Deutscher Apotheker Verlag, 85 S.
ISBN 978-3769266283

Schlesinger M., Bendas G.
Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis.
Cancer Metastasis Rev. 34 (2015) 575-91

Schlesinger M., Bendas G.
Vascular cell adhesion molecule-1 (VCAM-1)-An increasing insight into its role in tumorigenicity and metastasis.
Int J Cancer. 136 (2015) 2504-14

Hartung A., Bendas G.
Half-Life Extension with Pharmaceutical Formulations: Liposomes.
in: Therapeutic Proteins - Strategies to Modulate their Plasma Half-Lives
ISBN 978-3-527-32849-9
Edited by R. Kontermann
Publisher: Wiley Backwell 2012, 299-314.

Bendas G, Borsig L.
Cancer cell adhesion and metastasis: Selectins, integrins and the inhibitory potential of heparins.
Int J Cell Biol. 2012; 2012: 676731doi:10.1155/2012/676731

Alexander M., Bendas G.
The Role of Adhesion Receptors in Melanoma Metastasis and Therapeutic Intervention Thereof Source.
in: Research on Melanoma - A Glimpse into Current Directions and Future Trends
ISBN 978-953-307-293-7
Edited by: Mandi Murph
Publisher: InTech, September 2011

Reder-Christ K., Bendas G.
Biosensor Applications in the Field of Antibiotic Research—A Review of Recent Developments.
Sensors 2011, 11, 9450-9466; doi:10.3390/s111009450